These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23411735)

  • 1. Hemichorea in a patient with JAK2V617F blood cells.
    Lew J; Frucht SJ; Kremyanskaya M; Hoffman R; Mascarenhas J
    Blood; 2013 Feb; 121(7):1239-40. PubMed ID: 23411735
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm.
    Peyro-Saint-Paul H; Hermitte F
    Blood; 2010 Sep; 116(11):1994-5. PubMed ID: 20847214
    [No Abstract]   [Full Text] [Related]  

  • 3. Jakking up tumor registry reporting of the myeloproliferative neoplasms.
    Selinger HA; Ma X
    Am J Hematol; 2009 Feb; 84(2):124-6. PubMed ID: 19117021
    [No Abstract]   [Full Text] [Related]  

  • 4. Teaching Video NeuroImages: A treatable rare cause of chorea.
    Rossi M; Cammarota A; Merello M; Nogues M
    Neurology; 2018 Sep; 91(11):e1089. PubMed ID: 30201756
    [No Abstract]   [Full Text] [Related]  

  • 5. The JAK2V617F mutation: no impact on circulating hematopoietic progenitors in myeloproliferative disorders.
    Wappl M; Jaeger E; Kusec R; Schwarzinger I; Geissler K; Oehler L
    Ann Hematol; 2008 Jun; 87(6):509-11. PubMed ID: 18180923
    [No Abstract]   [Full Text] [Related]  

  • 6. Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.
    Pacilli A; Fanelli T; Mannarelli C; Rotunno G; Pancrazzi A; Vannucchi AM; Guglielmelli P
    Hematol Oncol; 2018 Feb; 36(1):357-359. PubMed ID: 28474777
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat
    Kearney L; Lee Tokar L; Flynn C; Mykytiv V; Murphy K; Langabeer SE
    J Clin Pathol; 2020 Nov; 73(11):772. PubMed ID: 32646925
    [No Abstract]   [Full Text] [Related]  

  • 9. Clearing the path for MPN therapy monitoring.
    Mesa RA
    Blood; 2013 Nov; 122(23):3704-5. PubMed ID: 24288406
    [No Abstract]   [Full Text] [Related]  

  • 10. JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
    Vannucchi AM
    Curr Hematol Malig Rep; 2010 Jan; 5(1):22-8. PubMed ID: 20425393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
    Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
    J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
    Ali FR; Roberts LN; Mistry H; Patel RK; Edmondson RA; Arya R
    J Vasc Surg; 2009 Jan; 49(1):211-3. PubMed ID: 19174256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis?
    Stolyar MA; Klimova OA; Gorbenko AS; Brenner EV; Titov SE; Ivanov MK; Olkhovskiy IA
    Int J Lab Hematol; 2018 Feb; 40(1):e8-e10. PubMed ID: 29134760
    [No Abstract]   [Full Text] [Related]  

  • 14. Fully automated and super-rapid system for the detection of JAK2V617F mutation.
    Tanaka R; Kuroda J; Stevenson W; Ashihara E; Ishikawa T; Taki T; Kobayashi Y; Kamitsuji Y; Kawata E; Takeuchi M; Murotani Y; Yokota A; Hirai M; Majima S; Taniwaki M; Maekawa T; Kimura S
    Leuk Res; 2008 Sep; 32(9):1462-7. PubMed ID: 18328559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooccurring
    Mambet C; Babosova O; Defour JP; Leroy E; Necula L; Stanca O; Tatic A; Berbec N; Coriu D; Belickova M; Kralova B; Lanikova L; Vesela J; Pecquet C; Saussoy P; Havelange V; Diaconu CC; Divoky V; Constantinescu SN
    Blood; 2018 Dec; 132(25):2695-2699. PubMed ID: 30377194
    [No Abstract]   [Full Text] [Related]  

  • 16. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).
    Hermouet S; Dobo I; Lippert E; Boursier MC; Ergand L; Perrault-Hu F; Pineau D
    Leukemia; 2007 May; 21(5):1128-30. PubMed ID: 17301814
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.